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Abstract 
Background: To assess the efficacy of intravenous 
immunoglobulins  in reducing the duration of 
phototherapy and the need for exchange transfusion 
in neonates with  Rh and/or ABO incompatibility. 
Methods: In this descriptive study 60 patients 
diagnosed with hemolytic disease of newborn were 
grouped into group A and B. All neonates were 
treated with standard protocol for phototherapy and 
exchange transfusion. Group A patients received 
intravenous immunoglobulins in a dose of 0.5gm/kg 
of body weight and phototherapy.Group B received 
only phototherapy. Exchange transfusion was given 
to the patients of both groups if the bilirubin 
reached 20mg/dl or more, or rose by 0.5 mg/dl per 
hour.     
Results:Mean pre and post treatment bilirubin 
levels were 14.87+ 4.45, 15.37+4.85 and 14.05+ 2.48, 
14.35+1.97 mg/dl in group A and B respectively. 
Improvement in bilirubin level was significant in 
group A 82.75% vs 48.38 % (CI: 95%, P-value 0.005). 
Similarly phototherapy duration was reduced in the 
same group 86.2% vs 16.1% (p-0.000). Exchange 
transfusion and hospital stay were also reduced in 
group A 3.4% vs 48.4%, 35.49 % vs 86.20% (95% CI, 
P=0.000) respectively.  
Conclusion: Addition of intravenous 
immunoglobulins for treatment of hemolytic disease 
of newborn significantly reduces bilirubin levels, 
duration of phototherapy, need for exchange 
transfusion and hospital stay. 
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Introduction 
     Hemolytic disease occurs when there is ABO ,Rh 
and minor blood groups incompatibility between the 
mother and the fetus.1 Incompatibility presentation 
ranges from mild hemolysis to severe anemia with 
enlargement of liver and spleen. Profound anemia can 
lead to hydrops fetalis. Indirect hyperbilirubinemia 
can lead to kernicterus.  ABO incompatibility is more 
common than Rh and other minor blood group 
incompatibilities, but clinically it is less severe.3 
     Modes of treatment commonly used to decrease the 
level of indirect bilirubin are phototherapy and 
exchange transfusion.1 There are two types of 
exchange transfusion; early and late. The indications 
for early exchange transfusions performed within 9 to 
12 hours of birth are ; cord hemoglobin levels 11 g/dl 
or less, cord bilirubin levels 5.5 mg/dl or greater, and 
rapidly rising bilirubin levels 0.5 mg/dl/hour or 
greater despite phototherapy.4 Early exchange 
transfusion has the advantage of replacing sensitized 
red cells with normal cells, thereby removing not only 
bilirubin but also the source of future bilirubin. As  
bilirubin is distributed in the extracellular fluids, 
efficiency is enhanced by removing sensitized cells 
early in the process. Late exchange transfusions are 
performed when serum bilirubin levels threaten to 
exceed approximately 20 to 22 mg/dl in term infants. 
An exchange transfusion should eliminate more than 
50 percent of the intravascular bilirubin. Intensive 
phototherapy effectively reduces bilirubin levels and 
decreases the need for exchange transfusions for 
hyperbilirubinemia in ABO and Rh hemolytic disease 
of the newborn. Exposure of bilirubin to light results in 
structural and configurational isomerization of 
bilirubin to less toxic and less lipophilic products  that 
are excreted efficiently without hepatic conjugation.5,6  
Phototherapy often is initiated at bilirubin levels less 
than 5 mg/dl in preterm infants with alloimmune 
hemolytic disease in order to avoid potentially risky 
exchange transfusions.4,7  
     Early administration of intravenous 
immunoglobulins after  diagnosis of neonatal immune 
hemolytic disease is made,  decreases the need for 
phototherapy and exchange transfusions.8,9 The 
decreased bilirubin levels in infants treated with 
intravenous immunoglobulins is attributed to 
reduction in hemolysis secondary to blockade of 
reticuloendothelial Fc receptors and therefore 
preventing the extravascular destruction of neonatal 
red blood cells by transplacentally acquired maternal 
antibodies. Administration of 0.5 to 1 g/kg over 2 
hours is recommended if total serum bilirubin levels 
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continue to rise despite intensive phototherapy or the 
total serum bilirubin level is within 2 to 3 mg/dl of the 
exchange transfusion level in 12 hours if necessary.4 
Patients and Methods 
       This descriptive study was conducted at Neonate 
intensive care unit in Pediatrics Department of Holy 
Family Hospital during June 2008-May 2009. Sixty 
neonates diagnosed with hemolytic disease of 
newborn were grouped into group A and B. Inclusion 
criteria included neonates of both sexes, both term and 
preterm with hemolytic disease of newborn. The 
babies in whom exchange transfusion indicated at 
presentation were excluded. Informed consent was 
taken from parents of each neonate. All the neonates 
underwent a detailed physical examination with 
anthopometry. The required investigations were 
hemoglobin, reticulocyte count , Coombs’ test and 
serum Bilirubin. The group A patients received 
intravenous immunoglobulins in a dose of 0.5gm/kg 
of body weight and phototherapy according to the 
normative tables. The group B received only 
phototherapy. Exchange transfusion was given to the 
patients of both groups if the bilirubin reached 
20mg/dl or more, or rose by 0.5 mg/dl per hour.  
Results 
     Out of 60 patients , mean age for group A patients 
was 2.72+SD 1.88 days. Maximum neonates were 
between 01 to 02 days of age (31%). In group B, mean 
age was 2.61+SD 1.45 days and maximum patients fell 
in the age group of 02 days that comprised of 
29%(Table 1). Of total  60 patients, 46.7% cases were 
females and 53.3% were males. In group A, 12 (41.3%) 
were female and 17 (58.6%) were male while 16 
(51.6%) female and 15 (48.3%) male patients in group 
B. Considering  the weight analysis, mean was 2.94 kg 
+ SD 0.40 however minimum weight was 2kg and 
maximum weight was 4.50kg Regarding the 
socioeconomic status of the patients, maximum 
patients were in partially affording class  with monthly 
income was between Rs.5000-10000 with n=26 while 
minimum number was recorded in affording class 
with average monthly income more than Rs.10000 
with n=6. Mean hemoglobin level and reticulocyte 
count of patients at start of study were 13.1±2.92 g/dl 
and 4.7±2.98 respectively. In group A Direct Coombs 
test was negative in 89.6% and positive in 10.3% while 
in group B it was negative in 93.5% and positive in 
6.4%. Majority (68.9%) patients had ABO 
incompatibility (Table 2). Decrease in bilirubin was 
more pronounced (82.7%) in group A as compared to 
group B (Table 3). Group A patients who received 
immunoglobulins required less days of phototherapy 
and duration of hospital stay was thus reduced  as 
compared to group B in which  stay was  more than 05 
days(Table 4).In group  A patients who received 
immunoglobulin treatment, only 3.4% needed 
exchange transfusion while on the other hand group B 
patients who were not treated with immunoglobulins 
needed more exchange transfusion 48.4%(Table 5).  
Table 1: Immunoglobulin therapy in haemolytic 
disease of newborn 
  
Received immunoglobulins Total 
Yes No  
Age 1-4 days 23(46.94%) 26(53.06%) 49 
  5-7 days 6(54.54%) 5(45.46%) 11 
Total 29 31 60 
Table2: HDN- type of incompatibility 
 Frequency Percent 
ABO type 37 61.7 
Rh type 12 20.0 
Both 11 18.3 
Total 60 100.0 
Table3:HDN- Change in bilirubin in patients in 
group A and B 
 Group A Group B Total 
Decrease in biliubin 24(82.75%) 15(48.38%) 39 
Increase in bilirubin 5(17.25%) 16(51.62  %) 21 
 29 31 60 
p value = 0.005 
Table- 4 Duration of therapy in patients  
of group A and B 
  Duration of therapy Group Total 
  A B  
1-4days 25(8.2%) 5(16.1%) 30 
 5-8days 4(13.8%) 26(83.9%) 30 
Total 29 31 60 
p- value = 0.000 
Table 5:  Number of patients who required 
exchange transfusion in both groups 
  
  
Group Total 
A B  
Exchange transfusion 
needed 
  
Yes 1 15 16 
No 28 16 44 
Total 29 31 60 
p value = 0.000 
Discussion 
    The effectiveness of immunoglobulins has been 
proven in many studies to lower down the bilirubin 
levels in patients with hemolytic disease of newborn. 
Early reduction of bilirubin levels will reduce the 
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number of phototherapy sessions, requirement for the 
exchange transfusion and stay in the hospital. All of 
these factors have significant impact on the morbidity 
and mortality of the patients. 10-12   
     Immunoglobulins have been used for the treatment 
of hemolytic diseases of newborn during intrauterine 
life to reduce the maternal antibody titer which has 
shown beneficial results.10,11 Effectiveness of 
immunoglobulins in treatment of hemolytic disease 
depends upon the early diagnosis. Analysis showed  
bilirubin levels were significantly reduced in patients 
who received immunoglobulins. 13-15           
     Exchange transfusion carries a lot of risks like 
anaphylactic reactions, transmission of infections and 
risk of sepsis in already diseased patient. However 
these complications can be over come with the 
introduction of immunoglobulins as it is evident from 
our study that immunoglobulins given in hemolytic 
disease of newborn  reduced the need for exchange 
transfusion and only3.4% needed exchange 
transfusion.15,16  Present study showed that 
immunoglobulins  reduced the hospital stay which is 
similar to the  data of study by F Alpay, SU Sarita et al, 
that duration of hospitalization in terms of hours were 
significantly shorter in IVIG group (p < 0.05) .17   
     High cost of these immunoglobulins makes their 
availability unachievable for majority. On the other 
hand, treating hemolytic disease of newborn with 
traditional approach of phototherapy and blood 
exchange will result in morbidity. This involves high 
financial resources and a developing country like 
Pakistan cannot afford prolonged treatment of hospital 
stay, increased use of phototherapy, blood transfusion 
requirements and ultimately the increased mortality. 
All of these factors would cause considerable 
constraints on hospital resources and will worsen the 
already over loaded hospital with poor economic 
grades. Considering all these issues in direct 
comparison with the cost of immunoglobulins appears 
important. Cost of immunoglobulins would be equal 
to or less than the expense of prolonged patient’s 
hospital stay, prolonged phototherapy and blood 
transfusion requirements. Although we did not 
register side effects related to immunoglobulins as a 
separate variable however no serious consequences 
were even noted or reported. This shows the safety 
profile of immunoglobulins over hazards of exchange 
transfusion.   
Conclusion 
Intravenous immunoglobulins for treatment of 
hemolytic disease of newborn have a significant role in 
reducing bilirubin levels, need of exchange 
transfusion, duration of phototherapy and hospital 
stay.  
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